Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Relmada Therapeutics (Nasdaq: RLMD) plans to discuss its third-quarter financial results on a conference call and webcast on November 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) plans to discuss its third-quarter financial results on a conference call and webcast on November 12, 2026. The call is scheduled for 4:30 PM ET and will cover the quarter ended September 30, 2026, alongside recent business progress. A webcast replay will be available in the Investors section of Relmada’s website.
Details
Market move: RLMD +11.20% in the Nov 3 session. 3Q26 earnings date
On Nov 3, the day this news came out, RLMD closed 11.20% above the previous close. Argus tracked a peak move of +17.4% during that session. Our momentum scanner recorded 36 alerts for this stock that day. That session’s volume was 1.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, November 12, 2026 at 4:30 PM ET
- Participant Dial-in (US): 1-800-717-1738
- Participant Dial-in (International): 1-646-307-1865
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
